

MAIN PUBLICATIONS

Nagem RAP, Colau D, Dumoutier L, Renauld JC, Ogata C, Polikarpov I. 2002. Crystal structure of recombinant human interleukin-22. *Structure*. **10**:1051-1062.

Menezes IRA, Lopes JCD, Montanari CA, Oliva G, Pavao F, Castilho MS, Vieira PC, Pupo MT. 2003. 3D QSAR studies on binding affinities of coumarin natural products for glycosomal GAPDH of *Trypanosoma cruzi* *Journal of Computer-Aided Molecular Design*. **17**:277-290.

Pavao F, Castilho MS, Pupo MT, Dias RLA, Correa AG, Fernandes JB, da Silva MFGF, Mafezoli J, Vieira PC, Oliva G. 2002. Structure of *Trypanosoma cruzi* glycosomal glyceraldehyde-3-phosphate dehydrogenase complexed with chalepin, a natural product inhibitor, at 1.95 angstrom resolution. *FEBS Letters*. **520**:13-17.

Silva M, Silva CHTD, lulek J, Thiemann OH. 2004. Three-dimensional structure of human adenosine phosphoribosyltransferase and its relation to DHA-urolithiasis. *Biochemistry*. **43**:7663-7671.

Vilar MM, Barrientos F, Almeida M, Thaumaturgo N, Simpson A, Garratt R, Tendler M. 2003. An experimental bivalent peptide vaccine against schistosomiasis and fascioliasis. *Vaccine*. **22**:137-144.

Ambrosio ALB, Nonato MC, de Araujo HSS, Arni R, Ward RJ, Ownby CL, de Souza DHF, Garratt RC. 2005. A molecular mechanism for Lys(49)-phospholipase A(2) activity based on ligand-induced conformational change. *Journal Of Biological Chemistry*. **280**:7326-7335.

Garcia W, de Araujo APU, Lara F, Foguel D, Tanaka M, Tanaka T, Garratt RC. 2007. An intermediate structure in the thermal unfolding of the GTPase domain of human septin 4 (SEPT4/Bradeion-beta) forms amyloid-like filaments *in vitro* *Biochemistry*. **46**:11101-11109.

Assmann EM, Alborghetti MR, Camargo MER, Kobarg J. 2006. FEZ1 dimerization and interaction with transcription regulatory proteins involves its coiled-coil region. *Journal of Biological Chemistry*. **281**:9869-9881.

Hesling C, Oliveira CC, Castilho BA, Zanchin NIT. 2007. The Shwachman-Bodian-Diamond syndrome associated protein interacts with HsNip7 and its down-regulation affects gene expression at the transcriptional and translational levels. *Experimental Cell Research*. **313**:4180-4195.

Coltri PP, Guimaraes BG, Granato D, Luz JS, Teixeira EC, Oliveira CC, Zanchin NIT. 2007. Structural insights into the interaction of the Nip7 PUA domain with poly-uridine RNA. *Biochemistry*. **46**:14177-14187.

RESEARCH, INNOVATION
AND DISSEMINATION CENTERS (RIDC)

MAIN RESEARCHERS

Director

Glaucius Oliva – São Carlos Institute of Physics / University of São Paulo (IFSC/USP)

Innovation Coordinator

Richard Charles Garratt (IFSC/USP)

Education Coordinator

Leila Maria Beltrami (IFSC/USP)

Ana Paula U.de Araújo (IFSC/USP)

Igor Polikarpov (IFSC/USP)

Otavio H. Thiemann (IFSC/USP)

Adriano D.Andricopulo (IFSC/USP)

Dulce H. F. de Souza – (DQ/UFSCar)

Paulo Cezar Vieira (DQ/UFSCar)

Arlene G. Corrêa (DQ/UFSCar)

Flávio Henrique da Silva (DGE/UFSCar)

Heloisa S. S. de Araújo (DCF/UFSCar)

Carlos H. Inácio Ramos (Unicamp/LNLS)

Jörg Kobarg (LNLS)

Nilson I. T. Zanchin (LNLS)

Celso E. Benedetti (LNLS)

Beatriz G. Guimarães (LNLS)

João Alexandre R. G. Barbosa (LNLS)

Ana Carolina de Mattos Zeri (LNLS)

Fabio Cesar Gozzo (LNLS)

Participant Institutions and Laboratories

São Carlos Institute of Physics / University of São Paulo (IFSC/USP)

Chemistry Department / Federal University of São Carlos (DQ/UFSCar)

Physiological Sciences Department / Federal University of São Carlos (DCF/UFSCar)

Genetics and Evolution Department / Federal University of São Carlos (DGE/UFSCar)

National Synchrotron Light Laboratory (LNLS)

State University of Campinas (Unicamp)



Crystal structure of the enzyme glyceraldehyde-3-phosphate dehydrogenase from *Trypanosoma cruzi*, one of the targets for anti-parasitic drug discovery at CBME

The major goal of the Center for Structural Molecular Biotechnology (CBME) is to perform both applied and basic research, as well as technological development in all areas that depend on Structure Based Molecular Design, specifically in the rational design of new structure-based compounds (drugs, vaccines, pesticides, herbicides) and in protein engineering. Our center promotes an integrated multidisciplinary approach including Molecular Biology, Biochemistry, Structural Biology, Medicinal Chemistry based on both Synthetic and Natural Product Chemistry, Molecular Immunology, Cell Biology and Pharmacology. Maximum integration and collaboration with the private sector is always sought, particularly with pharmaceutical and biotechnology companies and research institutes within the health and agricultural sectors. The integration of biological sciences with the facilities of the National Synchrotron Light Laboratory (LNLS) represents a major advantage for the center.

The research projects of CBME are selected by their focus on areas which are socially highly sensitive, such as human health, agriculture and the environment. The center aims to achieve maximum integration and partnership with both public and productive sectors, particularly national and international pharmaceutical companies, biotechnology industry, research institutions dedicated to human health and the agricultural sector. The large majority of the projects currently being developed are related to tropical parasitic diseases endemic in Brazil, as well as cancer, HIV and agricultural related diseases.

On the educational front, the center strongly invests in training programs for students and researchers in the area of Structural Biology in all institutions involved. Furthermore, the CBME will closely work with the Center for Scientific and Cultural Diffusion, which interacts with the community, through strong programs directed towards high school students, school teachers, libraries of experiments for school demonstrations, education at a distance via internet, videos, science fairs, lectures and so on.

The Center for Structural Molecular Biotechnology

Centro de Biotecnologia Molecular e Estrutural (CBME)
Avenida Trabalhador Sancarlene, 400
Parque Arnold Schmidt
13566-590 – São Carlos, SP – Brasil
<http://cbme.ifsc.usp.br>

MAIN RESEARCH TOPICS




The laboratories of CBME integrate top technologies in molecular biology, biochemistry, protein crystallography and medicinal chemistry

The common issue on the research projects of CBME is the molecular approach, in atomic detail, of biological systems related to demanding areas of society, such as human health, agriculture, and environment. The team members are researchers with solid formation and background in different aspects of molecular and structural biology. CBME's mission is to develop high-quality basic research in strategic areas for the country. The current main projects are related to endemic infectious diseases in Brazil, like Chagas' disease, leishmaniasis, schistosomiasis, yellow fever, malaria, and diarrhea. Other projects investigate proteins associated with cancer like septins, tubulin, Nek kinases and nuclear receptors; genetic diseases (Shwachman-Bondian-Diamond syndrome); anti-inflammatory drugs; plant-pathogen interactions; matrix metalloproteinases; disintegrins; myotoxins; and neurotoxins from Brazilian snake venoms; biological models of inflammation; and cellular signaling. The CBME research organization adopts a matrix arrangement, in which the heads of projects utilize all the available facilities, competences and skills, according to the projects' needs, thus optimizing the chances to achieve the established goals. These extensive external collaborations enable CBME to cover all the demanded methodologies and specialized techniques on developing projects.

By virtue of the strategic nature of CBME in pursuing partnerships with industry and research institutions, we are permanently open to set new challenges.

SUMMARY OF RESULTS TO DATE AND PERSPECTIVES



The antigenic protein SM14 is a vaccine candidate for the treatment of schistosomiasis. A model for its three-dimensional structure, built by CBME researchers in collaborations with Fiocruz (RJ), has aided in better understanding its immunological properties, and the development of novel immunogenic peptides

During its existence CBME has contributed significantly to the current body of knowledge in structural biology of many different systems. These include studies on proteins from human parasites (such as *T. brucei*, *T. cruzi*, *P. falciparum*, *S. mansoni*, *L. major* among others) many of which are related to essential metabolic processes within the parasite and therefore potential targets for chemotherapy. Equally important have been studies on proteins related to non-infectious human diseases, such as nuclear receptors, where the classical methods of structural biology have been complemented by medicinal chemistry approaches towards the design of novel ligands with potential therapeutic benefit. Other projects have an alternative emphasis, for example on the design of peptides for vaccination trials or for diagnostic purposes or for better understanding of the molecular mechanisms behind the disease process itself. Overall, the research team of the CBME has solved tens of different protein structures and their complexes over the last seven years of existence.

Not all effort is devoted to research in human health. The discovery of a large number of cysteine protease inhibitors, coded by sugar cane has led to the development of transgenic plants resistant to common plagues that severely damage crops. Such experiments are currently ongoing involving researchers from the CBME together with studies aimed at better understanding the molecular mechanisms involved in plant/pathogen relationships.

Such efforts in the research field have limited

impact without corresponding attempts to make them relevant to the academic community and to society in general. The CBME has become renowned both nationally and internationally for its outreach department, which involves the development of novel teaching aids, games, videos as well as for running teacher-training courses and for motivating high school children towards a career in the biomolecular sciences. Furthermore, the Center has collaborated with many industrial partners over the years including well-known national pharmaceutical companies such as Eurofarma, Cristalia and EMS, and its members are always aware of potential patenting possibilities. Indeed, several patents have been filed both nationally and internationally over the last few years. Licensing of some of those to private partners is under advanced negotiations.